Bantam Pharmaceutical is developing first-in-class small molecule oncology therapeutics for hematological cancers and select solid tumors – a $10 billion dollar market opportunity.
Bantam’s lead drug candidate is an orally available compound with a novel mechanism of action that activates the Integrated Stress Response through modulation of eIF2α and induction of the ATF4 pathway.
Bantam is seeking partners and investors to facilitate rapid progression of its clinical candidate through IND filing and proof of concept clinical trials.
POTENT IN VIVO ACTIVITY
NOVEL MECHANISM OF ACTION
In human tumor xenograft studies of Diffuse Large B-Cell Lymphoma, treatment (single agent, once daily dosing) with Bantam’s lead compound (BTM-3566) results in complete tumor regression, along with durable remission upon withdrawal. Studies demonstrate that Bantam’s compounds also exhibit substantial tumor growth inhibition in solid tumors – KRAS-mutated colorectal and lung cancer.
The compounds have a unique mechanism of action (MoA), distinct from currently known targeted therapeutics, including histone deacetylase, proteasome, and kinase inhibitors. The MoA is a series of actions that lead to activation of the eIF2α – ATF4 Integrated Stress Response pathway, and culminate with cancer cell apoptosis or suppression of tumor growth. Activation of the ATF4 pathway is specific: the compound does not activate other cellular stress pathways including DNA Damage, ER stress, Autophagy or Oxidative Stress. A unique set of patient selection markers have been identified that are functionally related to activation of the ATF4 ISR pathway by Bantam’s compounds.
Bantam’s compounds offer a new therapeutic approach that will expand the treatment options for relapsed and refractory DLBCL and difficult to treat solid tumors.
Bantam owns a rich intellectual property estate that includes the compounds and broad utility claims. Bantam has also filed patent applications that include claims related to the mechanism, production, indications, and routes of administration. These filings protect Bantam’s pipeline and any derivative products at least through 2038.
UNMET ONCOLOGY NEEDS
Bantam is committed to developing therapeutics that address the unmet needs of cancer patients. Proof of concept clinical studies will focus on lymphoid cancers and KRAS mutated solid tumors.
- Management team with extensive experience in oncology drug discovery and development from bench to market
- Accomplished scientific advisory board comprised of prominent academic and industry leaders
- Capital efficient operating model
SEEKING PARTNERS AND INVESTORS
Bantam is seeking financing and/or partners to initiate and complete CMC development, progress its lead program through IND-enabling studies and Phase 1a/1b clinical studies, and bring the Company to an exit via partnering event (licensing or acquisition by Pharma/Biotech companies) with a significant investor ROI.
For more information please fill out and submit the form, or contact: